ABSTRACT
Because of the hematogenous and lymphatic spread of endometrial cancer (EC), patients with recurrent or advanced disease often present with tumor outside of the pelvis. Systemic therapy, therefore, plays an important role in the management of these patients. Both hormonal and cytotoxic agents have activity in patients with advanced or recurrent EC. However, neither of these types of therapies is considered curative in patients with distant, metastatic disease.
